Lumasiran
- Generic Name
- Lumasiran
- Brand Names
- Oxlumo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1834610-13-7
- Unique Ingredient Identifier
- RZT8C352O1
- Background
Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. These patients experience frequent kidney stones, nephrocalcinosis, and renal failure.
...
- Indication
Lumasiran is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients.
- Associated Conditions
- Primary Hyperoxaluria Type 1 (PH1)
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath